Crystal commemorative recognizing team members in a first in-human clinical study of an anti-tumor therapy.
(9AJH024)
Crystal commemorative recognizing team members in a first in-human clinical study of an anti-tumor therapy.
(9AJH024)Custom Lucite, with an embedded drug vial, celebrating FDA approval of Cosela. (20ADH005)
Custom crystal celebrating FDA acceptance of the Investigational Drug Application for XTX101, a potential treatment for cancer patients.
(21AJH115)Crystal commemorative recognizing a collaboration involving Virginia Commonwealth University’s Medicine for All Institute.
(20AJH069)Crystal commemorative celebrating a development and commercialization agreement between Click Therapeutics and pharmaceutical firm Boehringer Ingelheim. The partnership centers on a mobile prescription app providing digital treatment for patients with schizophrenia.
(21AKL599)Lucite embedment with drug vial commemorating a study of a treatment for solid tumor cancer.
(21ADH006)Custom crystal commemorative celebrating the launch of Wynzora Cream, a topical treatment for plaque psoriasis that received approval from the FDA (Food and Drug Administration) in 2020. The product launch resulted from a collaboration agreement between Denmark-based MC2 Therapeutics, and EPI Health, a specialty pharmaceutical firm headquartered in Charleston, South Carolina.
(21ADH022)Custom crystal celebrating the submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA). The application, related to Impel NeuroPharma’s migraine treatment INP104, was supported by a Phase 3, open-label STOP-301 Trial.
(20ALJ356)Crystal tombstone commemorating an exclusive licensing agreement between Ovid Therapuetics and Angelini Pharma. The agreement centers on the development, manufacturing, and commercialization of a potential treatment for Angelman syndrome.
(20AJH130)
